Accendra Health

ACH

Market cap $215M

Investors need to pay close attention to Accendra Health stock based on the movements in the options market lately.

Accendra Health is upgraded to "Buy" after severe underperformance, trading at just 2x 2027 free cash flow. ACH faces significant margin pressure and a challenging balance sheet, with net leverage expected at 4.9-5x by end-2026. 2026 is likely a trough year due to a major contract loss; growth is expected to resume in 2027, aided by UnitedHealth volumes.

Accendra Health, Inc. (ACH) Q4 2025 Earnings Call Transcript

RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) today reported financial results for the fourth quarter ended December 31, 2025. Unless otherwise noted, the results herein reflect the Company's continuing operations, which primarily represent what was previously the Patient Direct segment and certain functional operations. “We ended the fourth quarter with the completion of the sale of the Products & Healthcare Services (P&HS) business on December 31, 2025, and we are.

RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the “Company”) plans to release financial results for the fourth quarter of 2025 on Thursday, February 19, 2026, after trading ends on the New York Stock Exchange. The Company will host a conference call for investors and analysts at 5:00 p.m. EST on the same day. Participants may access the call via the toll-free dial-in number at 1-888-300-2035, or the toll dial-in number at 1-646-517-7437. The conference ID access code is 105.

RICHMOND, Va.--(BUSINESS WIRE)--Owens & Minor, Inc. (NYSE: OMI) (the “Company”) announced the completion of the sale of its Products & Healthcare Services (P&HS) segment and the Owens & Minor brand to Platinum Equity and is renaming the publicly traded parent company Accendra Health, Inc. “Today's announcement marks an inflection point in the strategic transformation of Owens & Minor into Accendra Health, a leading nationwide pure play home based care platform. The completio.

RICHMOND, Va.--(BUSINESS WIRE)--Owens & Minor, Inc. (NYSE: OMI) (“the Company”) today announced that it will change its name to Accendra Health, Inc. with an anticipated effective date of December 31, 2025. The name change affects only the name of the parent corporation and is intended to better reflect the Company's strategic direction and future organizational focus as a leader in the home-based care market. The Company will continue to use and operate under the Apria and Byram Healthcare.

Owens & Minor, Inc. (OMI) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

RICHMOND, Va.--(BUSINESS WIRE)--Owens & Minor, Inc. (NYSE: OMI) announced today that members of its management team are scheduled to participate in two upcoming investor conferences. Citi 2025 Global Healthcare Conference On Tuesday, December 2, 2025, Ed Pesicka, the Company's President and Chief Executive Officer, and Will Parrish, the Company's Vice President of Strategy, Corporate Development, & Investor Relations, are scheduled to participate in a fireside chat at 2:30 P.M. ET and h.

Owens & Minor, Inc. ( OMI ) Q3 2025 Earnings Call October 30, 2025 5:00 PM EDT Company Participants Will Parrish Edward Pesicka - President, CEO & Director Jonathan Leon - Executive VP, CFO & Corporate Treasurer Perry Bernocchi - Executive VP & CEO of Patient Direct Segment Conference Call Participants Daniel Christopher Clark - Leerink Partners LLC, Research Division Kevin Caliendo - UBS Investment Bank, Research Division Daniel Grosslight - Citigroup Inc., Research Division Presentation Operator Good day, and thank you for standing by. Welcome to Owens & Minor's Third Quarter 2025 Earnings Conference Call.